Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SUGT1 divergent transcript (SUGT1-DT) is annotated in genomic databases as a non-coding transcript associated with the SUGT1 gene, but there is no direct evidence in the literature that it is a therapeutic target such as a receptor, enzyme, transporter, or regulator involved in drug actions or disease mechanisms. SUGT1-DT is identified by NCBI Gene 116435302 and Ensembl ENSG00000273723, but its molecular function, biological role, or involvement in disease remains unknown based on currently available public data. If the intent was to refer to SUGT1, a protein-coding gene with disease relevance, that would be a different target with more available functional and disease association data. Therefore, the entry as a target is likely incorrect, as SUGT1-DT is not the established therapeutic target, and its biological or pathological significance is not established in the scientific literature.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on SUGT1 divergent transcript (SUGT1-DT).